Stock ARVN ARVINAS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Arvinas, Inc.

Equities

ARVN

US04335A1051

Real-time Estimate Cboe BZX
Other stock markets
 12:39:26 2024-05-21 pm EDT 		5-day change 1st Jan Change
33.69 USD +1.29% Intraday chart for Arvinas, Inc. +7.88% -17.81%
May. 16 Sector Update: Health Care Stocks Steady Premarket Thursday MT
May. 16 Sector Update: Health Care MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Steady Premarket Thursday
MT
Sector Update: Health Care
MT
Correction: Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity
MT
Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity
MT
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
GL
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib
CI
Transcript : Arvinas, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:00 PM
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
GL
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
AQ
Oppenheimer Adjusts Arvinas Price Target to $70 From $80, Maintains Outperform Rating
MT
Arvinas Shares Up After Q1 Net Loss Narrows
MT
Earnings Flash (ARVN) ARVINAS Reports Q1 Revenue $25.3M
MT
Arvinas : Corporate Presentation – May 2024
PU
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
GL
Arvinas, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Arvinas to Present at Upcoming Investor Conferences
GL
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
GL
Arvinas, Inc. Appoints Randy Teel as Chief Business Officer
CI
Arvinas : 2024 Proxy Statement
PU
H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARVN Stock
  4. News Arvinas, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW